Cargando…
Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways
SIMPLE SUMMARY: Glaucoma is a chronic eye disease that is one of the leading causes of blindness worldwide. Currently, the only therapeutic option is to lower intraocular pressure. The onset of the disease is often delayed because patients do not notice visual impairment until very late, which is wh...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698915/ https://www.ncbi.nlm.nih.gov/pubmed/34943212 http://dx.doi.org/10.3390/biology10121296 |
_version_ | 1784620392575401984 |
---|---|
author | Auler, Nadine Tonner, Henrik Pfeiffer, Norbert Grus, Franz H. |
author_facet | Auler, Nadine Tonner, Henrik Pfeiffer, Norbert Grus, Franz H. |
author_sort | Auler, Nadine |
collection | PubMed |
description | SIMPLE SUMMARY: Glaucoma is a chronic eye disease that is one of the leading causes of blindness worldwide. Currently, the only therapeutic option is to lower intraocular pressure. The onset of the disease is often delayed because patients do not notice visual impairment until very late, which is why glaucoma is also known as “the silent thief of sight”. Therefore, early detection and definition of specific markers, the so-called biomarkers, are immensely important. For the methodical implementation, high-throughput methods and omic-based methods came more and more into focus. Thus, interesting targets for possible biomarkers were already suggested by clinical research and basic research, respectively. This review article aims to join the findings of the two disciplines by collecting overlaps as well as differences in various clinical studies and to shed light on promising candidates concerning findings from basic research, facilitating conclusions on possible therapy options. ABSTRACT: Glaucoma represents a group of chronic neurodegenerative diseases, constituting the second leading cause of blindness worldwide. To date, chronically elevated intraocular pressure has been identified as the main risk factor and the only treatable symptom. However, there is increasing evidence in the recent literature that IOP-independent molecular mechanisms also play an important role in the progression of the disease. In recent years, it has become increasingly clear that glaucoma has an autoimmune component. The main focus nowadays is elucidating glaucoma pathogenesis, finding early diagnostic options and new therapeutic approaches. This review article summarizes the impact of different antibodies and proteins associated with glaucoma that can be detected for example by microarray and mass spectrometric analyzes, which (i) provide information about expression profiles and associated molecular signaling pathways, (ii) can possibly be used as a diagnostic tool in future and, (iii) can identify possible targets for therapeutic approaches. |
format | Online Article Text |
id | pubmed-8698915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86989152021-12-24 Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways Auler, Nadine Tonner, Henrik Pfeiffer, Norbert Grus, Franz H. Biology (Basel) Review SIMPLE SUMMARY: Glaucoma is a chronic eye disease that is one of the leading causes of blindness worldwide. Currently, the only therapeutic option is to lower intraocular pressure. The onset of the disease is often delayed because patients do not notice visual impairment until very late, which is why glaucoma is also known as “the silent thief of sight”. Therefore, early detection and definition of specific markers, the so-called biomarkers, are immensely important. For the methodical implementation, high-throughput methods and omic-based methods came more and more into focus. Thus, interesting targets for possible biomarkers were already suggested by clinical research and basic research, respectively. This review article aims to join the findings of the two disciplines by collecting overlaps as well as differences in various clinical studies and to shed light on promising candidates concerning findings from basic research, facilitating conclusions on possible therapy options. ABSTRACT: Glaucoma represents a group of chronic neurodegenerative diseases, constituting the second leading cause of blindness worldwide. To date, chronically elevated intraocular pressure has been identified as the main risk factor and the only treatable symptom. However, there is increasing evidence in the recent literature that IOP-independent molecular mechanisms also play an important role in the progression of the disease. In recent years, it has become increasingly clear that glaucoma has an autoimmune component. The main focus nowadays is elucidating glaucoma pathogenesis, finding early diagnostic options and new therapeutic approaches. This review article summarizes the impact of different antibodies and proteins associated with glaucoma that can be detected for example by microarray and mass spectrometric analyzes, which (i) provide information about expression profiles and associated molecular signaling pathways, (ii) can possibly be used as a diagnostic tool in future and, (iii) can identify possible targets for therapeutic approaches. MDPI 2021-12-08 /pmc/articles/PMC8698915/ /pubmed/34943212 http://dx.doi.org/10.3390/biology10121296 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Auler, Nadine Tonner, Henrik Pfeiffer, Norbert Grus, Franz H. Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways |
title | Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways |
title_full | Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways |
title_fullStr | Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways |
title_full_unstemmed | Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways |
title_short | Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways |
title_sort | antibody and protein profiles in glaucoma: screening of biomarkers and identification of signaling pathways |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698915/ https://www.ncbi.nlm.nih.gov/pubmed/34943212 http://dx.doi.org/10.3390/biology10121296 |
work_keys_str_mv | AT aulernadine antibodyandproteinprofilesinglaucomascreeningofbiomarkersandidentificationofsignalingpathways AT tonnerhenrik antibodyandproteinprofilesinglaucomascreeningofbiomarkersandidentificationofsignalingpathways AT pfeiffernorbert antibodyandproteinprofilesinglaucomascreeningofbiomarkersandidentificationofsignalingpathways AT grusfranzh antibodyandproteinprofilesinglaucomascreeningofbiomarkersandidentificationofsignalingpathways |